3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Pancreatic Neoplasms
4
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Oxaliplatin
295
Capecitabine
209
Fluorouracil
183
Cisplatin
172
Docetaxel
140
S 1 (combination)
135
Paclitaxel
128
Leucovorin
117
Irinotecan
110
pembrolizumab
104
Trastuzumab
76
Nivolumab
59
apatinib
57
Drug Therapy
52
sintilimab
46
Surgical Procedures, Operative
45
Ramucirumab
40
Radiotherapy
40
Bevacizumab
37
Hyperthermic Intraperitoneal Chemotherapy
34
Epirubicin
32
titanium silicide
31
tislelizumab
31
Carboplatin
31
Gastrectomy
28
Cyclophosphamide
27
XELOX
25
Tegafur
24
Folfox protocol
23
Albumin-Bound Paclitaxel
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
rucaparib
×
Gastrointestinal
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts
NCT03995017
2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2
Unknown
34 enrolled